Background: Proprotein convertase subtilisin/xexin type 2 (PCSK2) is an endoproteinase responsible for proteolytic activation of a number of precursors to active neuropeptides and peptide hormones, known to influence glucose homeostasis, food intake and ultimately body mass. In this study, we examined the consequences of PCSK2 deficiency on these phenotypic traits. Study Design: Weight gain with age under diets of different fat contents was monitored. White adipose tissue (WAT) and muscle masses were evaluated. Plasma levels of triglycerides, leptin, ghrelin, insulin and proglucagon-derived peptides were measured as well as leptin and acetyl coenzyme-a carboxylase (ACCa) mRNA levels in adipose tissue.
Introduction
Proprotein convertase subtilisin/kexin type 2 (PCSK2), also known as proprotein convertase 2, is a member of the Kexinlike subfamily of eukaryotic endoproteinases implicated in the activation of secretory precursor proteins by cleavage after selected basic residues. PCSK2 is primarily expressed in neuronal and endocrine cells in which, together with PCSK1 and carboxypeptidase E, it mediates the proteolytic activation of precursors to a variety of neuropeptides and hormones. 1, 2 Generation of a PCSK2-null (Pcsk2 À/À ) mouse by Furuta et al. 3 has offered the opportunity to delineate the enzymatic link between this convertase and many neuroendocrine precursors, and to explore the physiological importance of its processing of these precursors. The original Pcsk2
À/À mouse, 3 which was a 129Sv:C57BL/6 (B6) mixed genetic background, seemed normal at birth, but grew at a slightly reduced rate. They showed chronic fasting hypoglycemia and enhanced glucose tolerance in an intraperitoneal glucose tolerance test. They were normoinsulinemic but severely hypoglucagonemic. Proteolytic activation of pancreatic islet prohormones was variably impaired: the impairment was more severe for a-cell proglucagon and d-cell prosomatostatin than for b-cell proinsulin. 3, 4 At 3 months of age, the islets of mutant mice showed marked hyperplasia of a-cells and d-cells and a relative diminution of b-cells. 3 Other physiological studies showed that these mice are prone to salt-induced hypertension 5 and stress-induced analgesia. 6 Other substrates whose processing is impaired in the Pcsk2 À/À mouse include precursors for pancreatic islet amyloid peptide, 7, 8 ileum neuropeptide Y, 9 pituitary and brain adrenocorticotropin, a-melanocyte-stimulating hormone 10 and b-endorphin, 11 brain cholecystokinin (CCK), 12 dynorphin, 13 neurotensin, 14 Met-enkephalin 15 and orphanin FQ/nociceptin. 16 Several of these peptides are known to regulate feeding: neuropeptide Y and b-endorphin are orexigenic, and CCK, neurotensin and a-melanocyte-stimulating hormone are anorexigenic. 17 Using subcongenic mapping of a SPRET/Ei donor DNA on Chr 2 in a B6 genetic background, Chiu et al. 18 have identified Pcsk2 as a positional candidate gene influencing body weight and adiposity. Mice homozygous for SPRET/Ei donor allele were leaner than their B6 counterparts and expressed less PCSK2 in their brain. 18 However, in another mouse study, a negative correlation was observed between body weight and the expression level of PCSK2 and 7B2, its specific chaperone and transient inhibitor. 19 In this study, we examine how food intake and body mass are affected by PCSK2 global deficiency in mice.
Materials and methods

Animals
The Pcsk2 À/À mice and wild-type (WT) control mice were littermates obtained from the mating of Pcsk2 À/ þ heterozygotes generated as described in Furuta et al. 3 Our mouse colony was initiated from a N4 backcross into the CD-1 genetic background. It was perpetuated by brother-sister heterozygous mating for 45 years. Four-week-old male C57BL/6 (B6) and B6.V-Lep(ob)/j ob/ob mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). All mice were housed in temperaturecontrolled rooms with 12-h dark-light cycles and, unless otherwise stated, were provided with food and drink ad libitum. They were handled according to the guidelines of the Canadian Council on Animal Care under a protocol approved by the institutional animal care committee. Unless otherwise stated, experimental mice were male and 8-12 weeks of age.
Weight gain, food consumption and adiposity To measure weight gain with age, 3-week-old male mice were kept on standard mouse chow and weighed weekly for 11 weeks and at 17 weeks. To evaluate white adipose tissue (WAT) and muscle mass, 7-and 17-week-old mice of both genders were weighed and killed by decapitation; their gonadal fat and gastroc muscle were immediately collected and weighed.
To assess food consumption, 4-month-old male mice were fasted for 16 h and then given free access to pre-weighed standard chow; the drop in chow weight was measured after 1, 2, 4, 6 and 24 h.
Dietary regimens
To study the effect of dietary fat on weight gain, 3-week-old mice were divided into groups (n ¼ 4-6/gender/genotype) and fed for 7 weeks a Research Diets (North Brunswick, NJ, USA) low-fat diet (LFD, catalog no. D12450) or a high-fat diet (HFD, catalog no. D12451), containing 10 or 45% kcal as fat, respectively. Body weight was recorded weekly.
To evaluate the effect of diet-induced obesity on the expression of PCSK2, 4-week-old B6 mice were fed either a HFD or a LFD for 8 weeks. RNA was then extracted from stomach and brain tissues.
Plasma hormone assays
Mice were fasted for 16 h, anesthetized under isoflurane (Abbott Laboratories, Montreal, QC, Canada) and bled by cardiac puncture. Plasma was separated from blood cells by centrifugation. Plasma levels of leptin, insulin, glucagon, glucagon-like peptide 1 (GLP-1) and amylin were measured using the LINCOplex Mouse Endocrine Immunoassay Panel (Linco Research, Inc., St Charles, MI, USA). Total plasma ghrelin was measured using total ghrelin RIA kit (Linco Research, Inc.).
Triglyceride assays
Plasma was collected from 16-h-fasted mice and assayed for triglyceride content using the Triglyceride Quantification Kit from Biovision (Mountain View, CA, USA).
Quantitative reverse transcriptase PCR Total RNA was extracted from brain, stomach and adipose tissue using TRIzol Reagent (Invitrogen, Burlington, ON, Canada). It was reverse-transcribed into complementary DNA using oligo dT-18 primer (100 ng mg -1 of RNA).
Quantitative PCR reactions were performed in 25 ml using 2 Peptide extraction and mass spectrometry analysis Plasma (100 ml) was diluted with an equal volume of 1 Â Trisbuffered saline, pH 7.6, containing 0.1% (volume/volume) Tween-20 and protease inhibitors (Complete Mini Protease Inhibitor Tablets; Roche). Immunoprecipitation and mass spectral analyses were carried out as previously described. 20 In brief, plasma was precleared with preimmune serum and supernatant subjected to immunoprecipitation with an antiglucagon antibody (Peninsula Laboratories, Belmont, CA, USA). Captured peptides were acid eluted from Protein-A beads and neutralized, and after size filtration through an Amicon Ultra YM30 Centricon (Millipore Corp., Bedford, MA, USA), they were subjected to a time-of-flight mass spectral analysis on a Ciphergen Protein Biology System II (PBS II; Ciphergen Biosystems, Fremont, CA, USA).
Statistical analysis
Data analysis was performed using Prism (v5.0) software (GraphPad Software, Inc., La Jolla, CA, USA). Data are reported as mean ± s.e.m. Two-way analysis of variance was used for multiple comparisons of feeding condition (HFD/ LFD) by mouse genotype, followed by Bonferroni post hoc tests. One-way analysis of variance was used for multiple comparisons between tissues or genotypes, followed by Tukey's post hoc tests. Differences with a Po0.05 were considered significant. , Po0.0005; Figure 1a ). As illustrated in Figure 1b , gastroc muscle mass (lean tissue) was similar between genotypes within gender. Differences in adiposity were significant in 17-week-old mice (females: 
Results
PCSK2 deficiency is associated with reduced body mass
Pcsk2 þ / þ ,
PCSK2 deficiency does not affect food intake
To assess whether the difference in body weight and fat mass between Pcsk2 À/À and their WT littermates is because of difference in their feeding behavior, we measured food intake in both genotypes for 24 h after an overnight fast. There was no difference between Pcsk2 À/À and Pcsk2
mice at any time point or in the 24-h cumulative food intake (data not shown). In both genotypes, plasma ghrelin levels
Reduced body mass and adiposity in PCSK2-null mice Y Anini et al were low in mice fed ad libitum; they increased twofold after an overnight fast and declined after 2 h of post-fast feeding. There were no significant genotype-specific differences in plasma ghrelin levels in any of the three feeding states (data not shown).
PCSK2 deficiency is associated with high plasma levels of glucagon-related peptides Similar to the original 129Sv:B6-Pcsk2 À/À mice, 3 our N4 incipient congenic CD-1 Pcsk2 À/À mice were mildly hypoglycemic, but normoinsulinemic relative to their Pcsk2
littermates, suggesting they were more insulin sensitive. Accordingly, they showed improved glucose tolerance in an intraperitoneal glucose tolerance test (data not shown). The 129Sv/B6-null mice had also been shown to contain increased levels of GLP-1 in pancreatic islets 21 as well as in an a-cell line derived from these islets. 22 But, to our knowledge, no study has analyzed the circulating proglucagon products in Pcsk2 À/À mice. Thus, we analyzed the circulating levels and forms of proglucagon-derived peptides in our Pcsk2 À/À mice. As expected, plasma from Pcsk2 À/À mice contained dramatically elevated levels of materials cross-reacting with anti-glucagon or anti-GLP-1 antibodies (not shown). Immunoprecipitation and mass spectrometric analysis of this material revealed that they included GLP-1, glicentin and proglucagon, confirming the defect in proglucagon processing in Pcsk2 À/À mice ( Figure 3 ).
PCSK2 deficiency resulted in decreased WAT, leptin and ACCa mRNAs
As reduced WAT in Pcsk2 À/À mice was not the result of reduced feeding, we sought to determine whether the WAT had altered gene expression. We tested the level of expression of the adipokine leptin and a key enzyme in the buildup of triglycerides, ACCa, in the WAT of Pcsk2 À/À mice, and compared it with their Pcsk2 þ / þ littermates. We observed significantly reduced leptin mRNAs in both male and female Pcsk2 À/À mice (Figure 4a ). The levels of ACCa mRNAs were significantly reduced in Pcsk2 À/À females but not in males (Figure 4b ). Reduced body mass and adiposity in PCSK2-null mice Y Anini et al PCSK2 deficiency is associated with reduced plasma triglycerides As fat metabolism genes were affected in the Pcsk2 À/À mice, we sought to determine whether the circulating levels of triglycerides were also affected. Both male and female Pcsk2 À/À mice had reduced levels of circulating triglycerides (162 vs 79 mg per 100 ml and 110 vs 75 mg per 100 ml, respectively, Figure 5 ).
WAT and Muscle
Obesity is associated with increased expression of Pcsk2 mRNA As PCSK2 deficiency was associated with decreased fat mass, we asked whether increased fat mass, as observed in obesity, could be associated with increased expression of this enzyme. We measured the steady-state levels of its mRNA in the brain and the stomach of diet-induced obesity mice, in their B6 lean control mice and in leptin-deficient ob/ob Reduced body mass and adiposity in PCSK2-null mice Y Anini et al mice. In the brain, the relative level of Pcsk2 mRNA was significantly elevated in diet-induced obesity mice and not in ob/ob mice. In the stomach, it was significantly elevated in both obesity models ( Figure 6 ).
Discussion
Our data show for the first time that Pcsk2 À/À mice have reduced adiposity and are less susceptible than their Pcsk2 þ / þ counterparts to fat-induced weight gain. The reduced adiposity cannot be attributed to decreased food intake as cumulative consumption over a 24-h period was similar between the two genotypes. PCSK2 is primarily expressed in the central nervous system, including the hypothalamus, as well as in the pituitary. 23, 24 It is also found in peripheral endocrine tissues, most particularly in the pancreas 25, 26 and the intestine. 27 In these organs, it mediates the production of a wide variety of appetite-controlling peptides. Comparative proteomics of the pituitary and hypothalamic extracts from WT and PCSK2-deficient mice have shown that several precursors to these peptides are either unprocessed or aberrantly processed. 11, 28 The fact that the mutant mice show normal food intake despite impaired production of orexigenic peptides suggests that a balance between orexigenic and anorexigenic peptides may have been maintained. In this study, we measured the levels of the orexigenic gastric hormone ghrelin: they were comparable between WT and PCSK2-null mice. This is consistent with the report showing that proghrelin is processed to the 28-amino acid active ghrelin by PCSK1 and not by PCSK2. 29 The reduced adiposity of Pcsk2 À/À mice may result from increased energy expenditure or from alterations in lipid uptake, utilization and storage. Alterations of lipid metabolism in these mice is suggested by the lower levels of circulating triglycerides and leptin as well as by the reduced expression of mRNAs for the key lipogenic enzyme ACCa and for leptin in adipose tissue. The decrease in leptin production may be a consequence of reduced fat tissue mass, as leptin levels are known to be positively correlated with body fat stores. 30 It did not affect food intake, which was comparable with that of WT controls. Leptin expression and secretion by adipose tissue have been shown to be upregulated by insulin 31, 32 and by CCK, 33 a hormone secreted by neurons and duodenal endocrine I cells. As plasma insulin levels are similar between Pcsk2 À/À and WT mice, the hypoleptinemia of mutant mice cannot be attributed to a deficit of this hormone. Pro-CCK processing is reportedly impaired in the neurons, but not in the intestine of Pcsk2 À/À mice. 34 It remains to be determined whether impaired processing of neuronal pro-CCK contributes to lowering of circulating leptin levels in these mice. In the periphery, the most significant peptidergic alteration in Pcsk2 À/À mice documented so far has been the absence of pancreatic glucagon. 3 In this study we show that PCSK2 deficiency is associated with a dramatic increase in pancreatic production and secretion of alternate glucagonprocessing products, most noticeably GLP-1. The elevated level of plasma GLP-1 found in Pcsk2 À/À mice may account for the better glucose tolerance showed by these mice. Indeed, GLP-1 potentiates glucose-induced insulin secretion, thus facilitating postprandial glucose disposal. 35 Leptin has Reduced body mass and adiposity in PCSK2-null mice Y Anini et al been shown to stimulate the secretion of GLP-1 from intestinal endocrine L cells. 36 In our Pcsk2 À/À mice, an increase in circulating GLP-1 levels is observed in the presence of a decrease in circulating leptin levels. We believe that the GLP-1 increase is mostly the consequence of increased proglucagon expression and its alternate processing by PCSK1 in pancreatic a-cells.
37,38
Interestingly, Conarello et al. 39 reported that glucagon receptor knockout mice (Gcgr
) showed decreased body weight and food intake, reduced plasma glucose levels, improved oral and intraperitoneal glucose tolerance, elevated GLP-1 plasma levels and reduced gastric emptying. When fed the HFD, these mice developed less hyperinsulinemia, less hyperleptinemia and no hepatic steatosis when compared with their WT controls. The phenotypic similarities between the Gcgr À/À mouse and the Pcsk2 À/À mouse suggest similar disturbances of glucagon metabolism. Genetic background is known to strongly influence the phenotype of Pcsk2 À/À mice. Thus, in a predominantly 129Sv genetic background, the mutation is associated with more plasma adrenocorticotropin and corticosterone than in a predominantly B6 background, causing a Cushing-like syndrome in the former but not in the latter. 40 Mice used in this study did not manifest this syndrome. It is uncertain to what extent the body mass phenotype described in this report is determined by the complex CD1/129Sv/B6 genetic components of these mice. The possibility that this phenotype is partly or entirely because of 129 alleles of genes located in a congenic donor region linked to Pcsk2 locus cannot be excluded. This issue could be clarified by comparing fully congenic mice developed in each of these genetic backgrounds or, alternatively, by generating PCSK2-null mice using syngeneic homologous recombinant embryonic stem cells and breeding mates.
The reduced insensitivity of the mutant mice to dietary fat is in contrast with the greater sensitivity that we have observed in female heterozygous mice carrying a large internal deletion at the Pcsk1 locus specifying PCSK1. 20 Thus, although PCSK1 deficiency promotes obesity, [41] [42] [43] [44] PCSK2 deficiency may protect from it. This is consistent with the results of Chiu et al., 18 showing that reduced expression of PCSK2 in the brain is associated with lower body weight and adiposity in mice. It seems to be inconsistent with the results of Farber et al. 19 who, using mouse Chr 2 congenic mice and F2 intercrosses, showed that congenic regions linked to increased expression of the PCSK2 chaperone 7B2 and increased PCSK2 activity in the pituitary were associated with lower body weight. Singlenucleotide polymorphisms common to mouse strains expressing high 7B2 were identified in the promoter region of the cognate gene, suggesting transcriptional regulation. It should be noted that, in the latter study, the level of pituitary a-melanocyte-stimulating hormone, a PCSK2-generated anorexic peptide, was unaltered in spite of the increase in PCSK2 activity. In addition, the increased activity was measured only in the pituitary, but not in other central and peripheral PCSK2-expressing tissues in which 7B2 gene transcription might be differentially regulated. Furthermore, it is unclear whether the observed weight increase was because of increased adiposity or increased growth. Finally, phenotypic comparison of PCSK2-null and 7B2-null mice has indicated that 7B2 could have other biological functions besides its activation of PCSK2. 45 Clearly, more studies are needed to explain the phenotypic discrepancies between these different mouse models. In summary, we have shown in this report that PCSK2 deficiency leads to reduced adiposity, resistance to dietinduced obesity, reduced circulating triglycerides and Reduced body mass and adiposity in PCSK2-null mice Y Anini et al improved glucose tolerance. In accordance, we have shown that obesity is accompanied with increased expression of PCSK2. These data suggest that this enzyme has a major role in the regulation of adiposity, body mass and glucose homeostasis. Its inactivation represents a potential strategy in the treatment of obesity or diabetes.
